|
Canada-0-LABORATORIES Company Directories & Business Directories
|
Company News:
- DBV Technologies | Dedicated to Improving the Lives of Patients with . . .
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively We are on a journey to advance epicutaneous immunotherapy, using our innovative technology, the VIASKIN ® patch
- Our Pipeline - DBV Technologies
Using our innovative VIASKIN ® patch technology, we are committed to developing a pipeline of food allergy product candidates that could potentially transform the care of food-allergic patients
- About DBV - DBV Technologies
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively
- Investor Overview - DBV Technologies
DBV’s food allergy programs include ongoing clinical trials of the VIASKIN ® peanut patch in children In addition to food allergies, the VIASKIN ® patch technology is also being investigated as a treatment option for other immunological disorders
- Contact Us - DBV Technologies
Châtillon DBV Technologies Bâtiment IRO 107 Av de la République 92320 Châtillon Phone: +33 (0)1 55 42 78 78
- News - DBV Technologies
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN ® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
- Careers - DBV Technologies
Bold innovation for a bold life At DBV Technologies, we celebrate full expression of our four core values and their associated professional behaviors Also known as the 4Cs, these values – Curiosity, Courage, Collaboration, and Credibility – are rooted in the DNA of our company
- DBV Technologies Announces €166. 7 Million in Gross Proceeds Following . . .
DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN ® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis
- Home FR | DBV Technologies
DBV Technologies est une entreprise biopharmaceutique internationale au stade clinique, fondée par des pédiatres convaincus que les allergies alimentaires pourraient un jour être traitées efficacement
- DBV Technologies to Present Additional Data from the VITESSE Phase 3 . . .
DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN ® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis
|
|